Organisation paid for research Program year 2025 Source: CMS Open Payments

Allergy & Asthma Specialists PSC

Neither a doctor nor a teaching hospital

Research payments

$343,495

317 payments

Through program year 2025, Allergy & Asthma Specialists PSC is reported as receiving $343,495 in research payments, across 317 payments.

By program year

5 rows

Year	Kind	Amount	Payments
2025	Research	$87,695	184
2024	Research	$98,828	74
2023	Research	$52,903	19
2022	Research	$95,985	35
2021	Research	$8,084	5

Breakdown

Who paid Research payments · program years 2021–2025

GlaxoSmithKline, LLC. $264,270 102 payments
Regeneron Pharmaceuticals, Inc. $79,224 215 payments

Studies the money was for Research payments · program years 2021–2025

A 52-Week, Randomised, Double-Blind, Double-Dummy, Parallel Group, Mul $208,217 73 payments
A U.S. Registry of Eosinophilic Esophagitis Patients Treated With DUPIXENT as Standard of Care $31,732 8 payments
Registry of Asthma Patients Initiating DUPIXENT (RAPID) $28,726 200 payments
A 52-Week, Randomised, Double-Blind, Placebo-Controlled, Parallel-Grou $22,602 22 payments
AIM4: Next Step - Asthma Uncontrolled With ICS in Medium Dose (GINA 4): Next Step; Efficacy of Dupilumab Added to Medium Dose ICS/LABA in Comparison to ICS Dose Escalation to High Dose ICS/LABA in Patients With Uncontrolled Asthma $18,766 7 payments
A Prospective, Real-World, Interventional Study to Evaluate the Effect $17,360 4 payments
A Multi-Centre, Single Arm, Open-Label Extension Study to Evaluate the $13,591 2 payments
A Randomised, Double-Blind, Parallel Group, Multicentre, Stratified, S $2,500 1 payment

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.